Apr 10 |
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
|
Apr 3 |
Aprea Therapeutics files to sell 4.39M shares of common stock for holders
|
Mar 11 |
Aprea Therapeutics announces private placement financing of up to $34M
|
Mar 11 |
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
|
Mar 11 |
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
|
Mar 5 |
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
|
Feb 6 |
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
|
Jan 26 |
Aprea Therapeutics files for $150M mixed shelf
|
Jan 4 |
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024
|
Oct 24 |
Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways
|